Eden vs Ro vs PlexusDx: GLP-1 Cost and Best Fit (2026) | PlexusDx

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re cross-shopping Eden and Ro for cash-pay GLP-1 weight loss in 2026, the headline numbers can be misleading. Eden advertises compounded semaglutide at $129 first month, then $249/mo on the 3-month plan or $229/mo on the monthly plan, all-inclusive. Ro advertises a $39 first month membership, then $149/mo — with brand-name medication billed separately on top. The two pages look comparable; in your bank account they aren’t. This article walks the actual annualized cost math, the medication-source difference (compounded vs FDA-approved branded), the safety considerations on each side, and where the PlexusDx Semaglutide Injection, Tirzepatide Injection, and Microdose GLP-1 Protocol sit relative to both — because the Eden vs Ro vs PlexusDx choice isn’t really about which company is “better.” It’s about medication source, oversight model, total annualized cost, and whether genetics inform your dose before week one.

Eden vs Ro vs PlexusDx — quick decision frame

Three pricing models cover the cash-pay GLP-1 market. Eden is an all-inclusive compounded-medication platform: compounded semaglutide runs $129 first month, then $249/mo (3-month plan) or $229/mo (monthly plan); compounded tirzepatide runs $249 first month, then $329/mo on the monthly plan. No membership fee, FSA/HSA eligible, all 50 states. Ro is a membership-plus-medication model: $39 first month then $149/mo for the Ro Body membership, with medication billed separately. Ro’s primary path is FDA-approved branded GLP-1s — Wegovy (pen and oral pill), Zepbound (KwikPen and vials), Ozempic, plus orforglipron through Foundayo — priced to match manufacturer-direct programs (NovoCare, LillyDirect). PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies — Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, Microdose GLP-1 Protocol at $129/mo flat, and GLP-Squared dual-compound at $249/mo — paired with the optional Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after your first month) so dosing is anchored to the patient’s GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants rather than starting from population averages. All three pricing models are cash-pay; PlexusDx and Eden charge no membership fee, while Ro layers its $149/mo membership on top of medication.

The real annual cost: Eden vs Ro vs PlexusDx

For a cash-pay patient with no insurance coverage for weight-loss drugs, Eden compounded semaglutide on the 3-month plan annualizes to roughly $2,428/year ($129 first month + $209 × 11), or about $2,648/year on the monthly plan ($149 first month + $229 × 11). Eden compounded tirzepatide runs about $3,868/year ($249 first month + $329 × 11). Ro’s membership alone runs $1,678/year ($39 first month + $149 × 11) — before any medication. Add Ro’s cash-pay branded options at manufacturer-matched pricing and many cost scenarios in the source comparison land in the $1,664–$2,578 range across six months, depending on which medication and dose; full-year branded totals can stretch well above that if insurance doesn’t pick up the medication. PlexusDx Weight Management Protocols range from $1,548/year on the Microdose GLP-1 Protocol ($129/mo flat) to $2,148–$2,748/year on Semaglutide Injection ($149/mo), $2,748–$3,708/year on Tirzepatide Injection ($249/mo), and $2,148–$3,900/year on GLP-Squared ($249/mo). Add $99 for the Precision Peptide Genetic Test as an add-on after month one and the genetic-baseline-included totals stay below Eden tirzepatide at the entry tiers. If insurance reliably covers Wegovy or Zepbound at a low copay, Ro is often the cheapest path. If it doesn’t — the case for most commercial plans in 2026 — PlexusDx’s Microdose protocol is meaningfully below both Eden and Ro at the entry tier, and PlexusDx Semaglutide Injection is competitive with Eden compounded semaglutide while bundling a genetic add-on path neither competitor offers.

Compounded vs FDA-approved branded — what each platform dispenses

This is the substantive medication difference and it’s worth understanding before signing up. Eden’s core all-inclusive plans dispense compounded semaglutide and tirzepatide — formulations prepared by a licensed compounding pharmacy. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. Eden also lists brand-name Ozempic, Wegovy, Mounjaro, and Zepbound, but its brand-name pricing through the platform is higher than manufacturer-direct programs. Ro’s primary path dispenses FDA-approved branded GLP-1 medications — Wegovy (semaglutide injection and oral tablet), Zepbound KwikPen, Zepbound vials, Ozempic, and the Foundayo orforglipron pill — the same finished products that ran the SUSTAIN, STEP, and SURMOUNT trials. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies, like Eden, but offer four delivery formats — weekly Semaglutide Injection or Tirzepatide Injection, daily oral, microdose troche/capsule/lozenge/sublingual, and a dual-compound semaglutide+tirzepatide stack — at protocol-specific dose ranges, paired with the optional genetic baseline. The compounded vs branded choice isn’t about effectiveness of the active ingredient; it’s about FDA approval status of the finished product, supply consistency, and which regulatory framework governs your medication.

Safety, side effects, and clinical oversight

All three programs prescribe medications in the GLP-1 receptor agonist class (and tirzepatide, a GIP/GLP-1 dual agonist). The FDA-labeled side-effect profile is well-characterized: nausea, diarrhea, vomiting, constipation, abdominal pain, and headache are common — most pronounced when starting and during dose increases — and typically improve over the first few weeks; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies; these medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The clinical-oversight question differs by platform. Ro routes prescriptions through licensed providers and partner pharmacies dispensing FDA-approved branded products; the FDA label and post-market surveillance apply directly. Eden routes through a licensed clinician and a compounding pharmacy with 24/7 patient-portal messaging. PlexusDx uses licensed U.S. compounding pharmacies and a clinical team that reviews the patient’s genetic test before titration when the test is included — a stratification step neither Eden nor Ro performs. PlexusDx is cash-pay, no membership, available in all 50 states (5 require a scheduled live consultation rather than async intake).

Why genetics matter before you choose

GLP-1 response varies meaningfully across patients. Variants in GLP1R (the GLP-1 receptor itself), GIPR (notably rs1800437, the headline variant for differential GLP-1 response), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights — so the prescribing clinician knows whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. Neither Eden nor Ro performs this step; both start from a population-average titration schedule and adjust based on subjective tolerability over the first 8–12 weeks. PlexusDx anchors that same conversation to a measurable genetic baseline, available standalone for $298 or as a $99 add-on after your first month on any protocol.

Which one fits — a four-question decision frame

Question 1: Does your insurance reliably cover Wegovy or Zepbound at a low copay? If yes, Ro’s insurance concierge is genuinely useful and the branded route is likely cheapest. Question 2: Are you cash-pay with no GLP-1 coverage and price is the dominant factor? Compare Eden compounded semaglutide at ~$2,428–$2,648/year against PlexusDx Microdose GLP-1 Protocol at $1,548/year or Semaglutide Injection at $2,148–$2,748/year. Question 3: Do you want the FDA-approved branded product specifically? Ro is the only one of the three that primarily dispenses Wegovy or Zepbound directly. Question 4: Do you want a genetic baseline informing dose and titration before the first injection? PlexusDx is the only option in this comparison that includes the Precision Peptide Genetic Test as part of the protocol pathway.

Frequently asked questions

Is Eden cheaper than Ro?

For cash-pay patients, Eden is often cheaper because there’s no separate membership fee on top of medication. Ro can win when commercial insurance covers a branded GLP-1 at a low copay. PlexusDx Microdose GLP-1 Protocol at $129/mo flat undercuts Eden’s lowest published rate — worth comparing alongside both.

Does Ro’s $149 membership include the medication?

No — Ro’s $39 first-month then $149/mo membership covers provider visits, coaching, labs, and insurance concierge, but the medication is billed separately. That’s the line that trips up most Eden vs Ro comparisons. PlexusDx and Eden are both no-membership all-inclusive: medication, consult, and shipping in one price.

Are compounded GLP-1 medications FDA-approved?

No. Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies and are not FDA-approved finished drug products. Branded Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved. PlexusDx, Eden, and Ro’s compounded paths all use the same active ingredients found in those branded products.

Which is better if I have insurance that covers Wegovy or Zepbound?

Ro is the strongest fit — the insurance concierge handles prior authorization for FDA-approved branded GLP-1s, which Eden and PlexusDx don’t do. PlexusDx is cash-pay only with no insurance billing. If your plan reliably covers Wegovy or Zepbound at a low copay, Ro is usually the cheapest path overall.

Which is cheapest if I’m paying cash with no GLP-1 coverage?

At the entry tier, PlexusDx Microdose GLP-1 Protocol at $1,548/year is below both Eden compounded semaglutide (~$2,428–$2,648/year) and Ro’s membership-plus-medication stack. PlexusDx Semaglutide Injection at $149/mo is competitive with Eden compounded semaglutide. No membership fee on either side.

Does Eden offer compounded tirzepatide?

Yes — Eden lists compounded tirzepatide at $249 first month, then $329/mo on the monthly plan, all-inclusive. PlexusDx Tirzepatide Injection runs $249/mo across six dose levels and includes the option to add the Precision Peptide Genetic Test for $99 after month one.

Does any of these include genetic testing before titration?

Only PlexusDx. The Precision Peptide Genetic Test is $298 standalone or $99 as an add-on after your first month, mapping 48 genes and 57 variants — including the GIPR rs1800437 variant linked to differential GLP-1 response. Eden and Ro start from population-average titration; PlexusDx anchors that conversation to a measurable baseline.

Related reading on PlexusDx

Related reading on PlexusDx: GLP-1 Cost, Semaglutide Cost, Tirzepatide Costs, Cheapest GLP-1.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Pricing for Eden and Ro is based on each provider’s published rates as of April 2026; actual costs may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision with a licensed clinician.